Diurnal Group PLC - Cardiff, Wales-based pharmaceutical company focused on hormonal diseases - Signs agreement with Er-Kim Pharmaceuticals for the distribution of paediatric adrenal insufficiency drug Alkindi and cortisol deficiency drug Chronocort in Turkey. Under the terms of the agreement, Er-Kim will receive the exclusive rights to distribute and when approved, market Alkindi and Chronocort in Turkey.
Alkindi is already approved in Europe, Israel and Australia and was approved in the US as Alkindi Sprinkle in September 2020. Chronocort is under review by the European Medicines Agency and the UK Medicines and Healthcare products Regulatory Agency. If the review is successful, a marketing authorisation opinion for approval is expected in the fort quarter of 2021.
Current stock price: 66.33 pence
Year-to-date change: up 16%
By Ife Taiwo; ifetaiwo@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
